Your SlideShare is downloading. ×
0
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Wilson’s disease   an update on diagnosis &
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Wilson’s disease an update on diagnosis &

3,078

Published on

hepatology cme- …

hepatology cme-
division of gastroenterology, mgm medical college ,indore

Published in: Health & Medicine
1 Comment
4 Likes
Statistics
Notes
  • Thanks you so much for sharing such an important and good information.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total Views
3,078
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
237
Comments
1
Likes
4
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. WILSON DISEASE - AN UPDATE ONDIAGNOSIS & TREATMENTGUIDE- DR.ATUL SHENDECANDIDATE-DR.SARATH MENON.RDIVISION OF GASTROENTEROLOGYMGM MEDICAL COLLEGE,INDORE
  • 2. INTRODUCTION Copper Metabolism Clinical Profile Spectrum of disease Diagnostic approach Treatment & Monitoring Prognosis & recovery
  • 3. COPPER METABOLISM Recommended – 0.9 mg/d Absorbed from duodenum & prox.SI Transported in portal circulation bound protein to liver Liver synthesize Cu bound ceruloplasmin & excrete copper into bile Stored in liver bound with metallathionein
  • 4. HISTORY
  • 5. WILSON DISEASE 1912- by Samuel alexander Kinnear Wilson- ’progressive lenticular degeneration” Autosomal recessive 1993- ATP 7B gene in chromosome 13 Failure of excretion of Cu into bile Failure of incorporate Cu to ceruloplasmin Serum “Free” copper toxicity Copper deposits in brain,kidney,cornea & organs
  • 6. CLINICAL PROFILE Age – any individual b/w 3- 55 yr with liver abnormalities of uncertain cause Age alone is not a criteria for exclusion Majority -5- 40 yr
  • 7. KF RINGS Kayser-Fleischer ring- Cu in descemets memb. Slit lamp examination Non-specific- c/c cholestatic disorders 30-50% in hepatic cond. & pre-symptomatic 99% in neuro-psychiatric presentations In children with liver d/s, KF rings usually absent Absence of KF rings doesn’t exclude diagnosis even in neurological disease
  • 8. SPECTRUM OF DISEASE Hepatic- - asymptomatic hepatomegaly - isolated splenomegaly - persistent elevation of AST,ALT - fatty liver - acute hepatitis - c/c hepatitis - autoimmune hepatits - cirrhosis-compensated/decompensated - acute liver failure
  • 9.  Neurological- often second-third decade - movement disorder(tremor,dystonia) - drooling,dysarthria,spasticity - pseudo bulbar palsy - dysautonomia - migraine,headaches - insomnia - seizures
  • 10.  Psychiatric- - depression - neurotic behavior - personality changes - frank psychosis Hematological- - Coombs neg. hemolytic anemia - transient jaundice - acute intra vascular hemolysis
  • 11.  Ocular- KF rings, sunflower cataract Cutaneous- lunulae ceruleae Renal – nephrolithiasis Skeletal-premature osteoporosis,arthritis CVS- cardiomyopathy,arrhythmias Pancreatitis Hypoparathyroidism Infertility,miscarriages
  • 12. DIAGNOSIS Liver function tests S. ceruloplasmin Urinary copper excretion Hepatic parenchymal copper concentration Liver biopsy Neuro radiological imaging Genetic studies
  • 13. S.CERULOPLASMIN Synthesized in liver-acute phase reactant 6 Cu atoms incorporated Normal – 18-35 mg/dl < 20 mg/dl + KF rings consistent with WD LOW levels seen in renal d/s,ESLD Level < 5 mg/dl- strong evidence of WD Subnormal levels needs further test Normal level doesn’t exclude Dx.
  • 14. S.COPPER Increased level of serum “free” copper Serum free Cu is non-ceruloplasmin bound Cu Total S.Cu (mcg/dl)- 3x serum ceruloplasmin Cu (µg/dl) Normal level- <15 mcg/dl > 25 mcg/dl in untreated WD < 5mcg/dl indicates over-treated
  • 15. URINARY COPPER 24 hr urinary Cu excretion Dx & monitoring Basal 24 hr urine Cu > 100 µg in symptomatic WD But > 40 µg may indicate WD , req. further test Pencillamine challenge test 500 mg D-pencillamine orally at beginning and repeat after 12 hr during 24hr urine collection > 1600 µg Cu/24 hr urine - positive
  • 16. HEPATIC PARENCHYMAL COPPERCONCENTRATION Normal - <40-50µg/g dry wt. liver Critical value- > 250 µg/g dry wt. Further evaluation needed if 70- 250µg/g ,if active liver d/s or symptoms of WD
  • 17. LIVER BIOPSY Mild steatosis- earliest Auto immune hepatitis histo.findings Cirrhotic changes-macronodular a/c liver failure- marked hepatocellular degeneration & parenchymal collapse Cu staining is variable- poor predictive value
  • 18. NEURO-IMAGING MR imaging- evaluate neurologic WD & prior to treatment MRI- T2 hyperintensity in basal ganglia,thalami
  • 19. GENETIC STUDIES Mutation analysis by whole gene sequencing in pt whom clinical & biochemical testing borderline Haplotype analysis based on polymorphism or spf.mutation testing- family screening of 1st.degree relative of WD.
  • 20. SPECIFIC TARGET POPULATION “Mimic” liver disease- - young & adult with features of auto immune hepatitis - not responding to steroid Rx. - hepatic steatosis ≈ NAFLD Acute liver failure - coombs neg hemo.anemia - a/c intravascular hemolysis - a/c renal failure -modest rise in ALT,AST <<1000U/L - NL or subnormal ALP <40U/L - ALP: S.Bil - < 2 - F:M – 2:1
  • 21.  Family screening- - 1st degree relatives - KF ring,24hr U.Cu -ATP7B Mutation analysis - Rx diagnosed case >3 yr age Newborn screening- - ceruloplasmin in blood spots & urine samples
  • 22. Unexplained liver d/s KF Ring + KF Ring + KF Ring- KF Ring –CPN <20mg/ CPN=20 CPN <20 CPN<2024h.U.cu>40 24h.U.cu>40 24h.U.cu=>40 24h.U.cu >40 Liver biopsy- histology &cu quantification >250mcg/g 70- <50 mcg/g 250mcg/g Molecular testing Other diagnosis Diagnosis of WD
  • 23. Neuropsychiatric +-liver d/s KF Ring + KF Ring- KF Ring + KF Ring + CPN>=20 CPN <20 CPN <20 CPN>20 24hU.cu>40 24hU.cu>40 24hU.cu>40 24hU.cu<40 Liver biopsy cu quantification Other Dx70-250 >250 Molecular testing Diagnosis WD
  • 24. Sibling Child>2 yr (asymptomatic) Slit lamp(>4 yr) CPN LFT Haplotype/ INR Mutation 24 h U.cu analysis Abn.LFT CPN<20 24h U.cu >40Identical haplotype or2 mut. 70-250 Liver biopsy Diagnosis WD >250
  • 25. TREATMENT Anti –copper drugs- -D-Pencillamine - Zinc - Trientene - Tetrathiomolybdate(TM) Diet Drinking water Concomitant hepatic,neurological management Liver transplantation
  • 26. ANTI COPPPER DRUGSDrugs Mode of Neurologica S/E Dosage monitoring action l deterioratio n 1 250- 24hr.U Cu- 500mg/d,incr 200-500µg emental Free Cu-D- Chelator 20-40 % in BM 250mg4-7d 10-15µg/dlpencillamine induces initial phase suppression, Max.1-1.5g/d cupuria nephrotic ( 2-4 doses) 1,3,6,12,18, syndrome, Maint- 24 months Hepatotoxicit 750mg-1g Then y,fever, Pyridoxine- annually 25mg/d
  • 27. DRUGS MODE OF SIDE EFEECTS DOSAGE MONITOR ACTION 24hr U.Cu & 750-1500mg/d Non-ceruloplas (2-3 doses) Bound copperTrientine Chelator induces Gastritis,aplastic 20mg/kg/d(child 1,3,6,12,18,24 cupuria anemia rare, Maint- months- Sideroblastic 750-1000mg annually anemia 24hr .U.Cu- Metallothione Gastritis,pancrea 150mg/d in 3 50-125µg/d Zinc inducer, titis,Zn divided doses & Inhibits Cu accumulation 75mg/d 24h.U.Zn absoption (child, <50 kg) > 2mg/d 3,6 months,6 month 2yr,then yearly
  • 28.  Tetra thiomolybdate- - inhibit CU absorption - bind with copper (chelator) - used in neurological WD - S/E- anemia,neutropenia, hepatotoxicity - 120 mg/d ie. 20mg x 3 with meal 60mg bed time - 8 weeks therapy - weekly neurological examination
  • 29. ZINC – THE NEW PARADIGM Reduces free Cu toxicity Normalise free Cu level in blood Induces metallothionein Store Cu in liver & in mucosal cells- promote Cu excretion via stools Less side effects Dosage- < 6 yr – 25 mg elemental Zn bd - 6-15 yr or 125 pds- 25 mg TDS - > 16yr or >125 pds- 50 mg TDS
  • 30. WILSON D/S- HEPATIC –INITIAL RXPatient type 1 st drug choice 2nd drug choiceTransaminases elevated,No hepatic failure Zinc TrientineCirrhosis presentcompensated Zinc TrientineCirrhosis decompensated Trientine + Zinc D-Pencillamine + ZincMild,Moderate hepaticfailureSevere hepatic failure Hepatic transplant Trientine + Zinc
  • 31. NAZER PROGNOSTIC INDEXLab normal Score Score Score Score Scoremeasure value 0 1 2 3 4mentSerum 0.2-1.2 <5.8 5.8-8.8 8.9-11.7 11.8-17.5 >17.5bilirubinSGOT 10-35 <100 100-150 151-200 201-300 >300PT 12-14s <4s 4-8s 9-12 13-20 >20prolongation diff.
  • 32. NAZER INDEX Mild hepatic failure- score <6 Moderate hep.failure- 7-9 Severe hep. Failure - >9
  • 33. WILSON D/S-NEUROLOGIC –INITIAL RX 1st choice- TM + Zinc 2nd choice- Zinc alone
  • 34. MAINTANANCE THERAPY Maintanance therapy- - after 2-4 month initial Rx. cut off value to begin- - U.cu < 150µg/24h (if Zinc is used alone) - S.”Free” Cu- < 25µg/dl Initiated from beginning in pre-symptomatics (only elevation of transaminases) 1st drug choice- Zinc 2nd drug choice- Trientine annual 24hr urine Cu & serum.free Cu monitor
  • 35. PRE-SYMPTOMATICS Diagnosed prior to clinically ill Siblings of affected patient d/t screening Incidental KF rings + Mild rise in serum transaminases Start directly maintenance regime with zinc(1st choice ) or trientine (2nd choice)
  • 36. PREGNANT Ist choice- Zinc 2nd choice- trientine D-pencillamine is teratogenic Copper deficiency is teratogenic If Zn used- urine Cu- 75- 150µg/24hr If Trientine used- S.free Cu- 15-25µg/dl Monitor every 3 months
  • 37. DIAGNOSED WDpresymptomatic hepatic neuropsychiatric 1.Zinc 1.TM+ Zinc 2.Trientine 2.Zinc Transaminase Elevation only Hepatic failure 1.Zinc Mild/mod Severe2.Trientine Nazer< 9 Nazer >9 1.Zn Liver +Trientine transplant
  • 38. DIET Avoid liver ,shell fishes,nuts,chocolate,mushroom After 6-12 months Rx, one meal + shell fish/ wk If enteral feeding,Cu <1.5 mg/d Drinking water - < 0.1 ppm Cu
  • 39. ACUTE LIVER FAILURE Liver transplantation Nazer score > 9 ARF- hemofiltration - plasmapheresis - hemodialysis
  • 40. LIVER TRANSPLANTATION Indications- - Nazer score >9 ,liver failure - failure of medical therapy in in decompensated failure Not indicated in neurological WD
  • 41. MONITORING Clinical & biochemical improvement LFT 24h U.Cu – - 200-500µg/d (d-Pen or trientine) - 50- 125 µg/d (Zinc) Non-ceruloplasmin bd.Cu(free cu) - 10- 15 µg/d 24 h U.Zn - >= 2mg/d
  • 42. RECOVERY,PROGNOSIS In hepatic failure, Rx with Zn + trientine Albumin,S.BR,SGOT -normal by 1 yr Cirrhosis,PHTN,hypersplenism – persists Neurological improvement-5-6 months & improve over 18 months Residual abn. After 24 month of Rx- permanent Speech improves afterwards also. Psychiatric /behavioral improves by 1-2 yr.
  • 43. SUMMARY WD- is an medical enigma with wide spectrum Proper clinical examinations Integrated diagnostic approach Treatment for various clinical profiles Zinc as a new paradigm shift in Rx Hepatic transplantation Monitoring., and prognosis Lifelong Rx and normal expectancy Fatal if not treated.
  • 44. THANK U….

×